C-SD0WCleara
peptide therapeutics, impaired-p53 targeting, apoptosis
clearingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-SD0W
C-SD0WC-SD0Wpeptide therapeutics, impaired-p53 targeting, apoptosis
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Cleara peptide therapeutics, impaired-p53 targeting, apoptosis
Cleara Biotech is a biopharmaceutical R&D company developing peptide-based therapies against cancer and chronic diseases. Its platform is designed to safely and selectively eliminate cells with impaired p53 signaling. The company’s lead development candidates, CL04177 and CL04183, are being advanced toward clinical trials in solid tumors and hematological malignancies.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Cleara — Early mechanism · Bottom quartile. Derived deterministically from 3 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (3 programs at preclinical).…
Source: Deterministic